|
101
|
Product specific BE guideline |
Sitagliptin phosphate tablet_生體相等性試驗指導原則
|
2019-10-01 |
|
102
|
Product specific BE guideline |
Tenofovir Disoproxil Fumarate Tablet_生體相等性試驗指導原則
|
2019-10-01 |
|
103
|
Product specific BE guideline |
Ezetimibe+Simvastatin Tablets_生體相等性試驗指導原則_v2(新增QA)
|
2019-10-01 |
|
104
|
Product specific BE guideline |
Ezetimibe Tablets_生體相等性試驗指導原則_v2(新增QA)
|
2019-10-01 |
|
105
|
Product specific BE guideline |
Sildenafil Citrate Tablets_學名藥生體相等性試驗指導原則
|
2019-01-08 |
|
106
|
Product specific BE guideline |
Dabigatran Etexilate Mesylate Hard Capsules_學名藥生體相等性試驗指導原則
|
2019-01-08 |
|
107
|
Clinical |
腸病毒疫苗臨床研發策略指導原則(第二版)
|
2018-11-28 |
|
108
|
Quality |
病毒載體之基因治療製劑化學製造管制研發策略指導原則
|
2018-11-28 |
|
109
|
Pharm/tox |
藥品光安全性評估指導原則
|
2018-11-28 |
